Humacyte, Inc. (NASDAQ:HUMA) Receives Average Rating of “Buy” from Analysts

Humacyte, Inc. (NASDAQ:HUMA) has received an average recommendation of “Buy” from the eight analysts that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $13.71.

A number of equities research analysts have issued reports on HUMA shares. Piper Sandler set a $6.00 target price on Humacyte and gave the company a “neutral” rating in a research note on Friday, October 18th. D. Boral Capital reissued a “buy” rating and set a $25.00 target price on shares of Humacyte in a research note on Monday, January 13th. TD Cowen restated a “buy” rating and issued a $10.00 price target on shares of Humacyte in a research note on Friday, October 18th. Benchmark boosted their price objective on Humacyte from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, December 23rd. Finally, BTIG Research restated a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th.

Humacyte Trading Down 1.6 %

Shares of NASDAQ HUMA opened at $4.41 on Monday. Humacyte has a 12-month low of $2.53 and a 12-month high of $9.97. The company has a market cap of $555.04 million, a price-to-earnings ratio of -3.29 and a beta of 1.32. The stock’s 50 day simple moving average is $4.58 and its 200 day simple moving average is $5.66.

Insider Buying and Selling at Humacyte

In other news, Director Brady W. Dougan sold 427,459 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the sale, the director now directly owns 1,992,253 shares of the company’s stock, valued at $8,646,378.02. The trade was a 17.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Laura E. Niklason sold 811,172 shares of the stock in a transaction on Monday, November 18th. The shares were sold at an average price of $4.44, for a total value of $3,601,603.68. Following the completion of the transaction, the chief executive officer now owns 2,419,712 shares of the company’s stock, valued at $10,743,521.28. This trade represents a 25.11 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,500,000 shares of company stock valued at $6,606,799. 11.20% of the stock is owned by corporate insiders.

Institutional Trading of Humacyte

Several institutional investors and hedge funds have recently bought and sold shares of HUMA. State Street Corp boosted its holdings in shares of Humacyte by 66.1% in the third quarter. State Street Corp now owns 4,764,155 shares of the company’s stock worth $25,917,000 after buying an additional 1,895,529 shares during the period. Millennium Management LLC boosted its stake in Humacyte by 504.3% in the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after purchasing an additional 1,334,641 shares during the period. Renaissance Technologies LLC grew its position in Humacyte by 693.0% during the 2nd quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock worth $2,881,000 after purchasing an additional 524,600 shares in the last quarter. Marshall Wace LLP raised its stake in Humacyte by 3,301.5% during the 2nd quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock valued at $2,226,000 after purchasing an additional 450,031 shares during the period. Finally, Deerfield Management Company L.P. Series C purchased a new stake in shares of Humacyte in the second quarter valued at $1,550,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.